DrugPatentWatch Database Preview
Patent: 9,364,567
» See Plans and Pricing
Summary for Patent: 9,364,567
| Title: | Fragments of p97 and uses thereof |
| Abstract: | Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB. |
| Inventor(s): | Vitalis; Timothy Z. (Vancouver, CA), Gabathuler; Reinhard (Montreal, CA) |
| Assignee: | biOasis Technologies, Inc. (Richmond, CA) |
| Application Number: | 14/210,029 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,364,567
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | Orphan | search |
| Wyeth Pharms Inc | MYLOTARG | gemtuzumab ozogamicin | VIAL;SINGLE-DOSE | 761060 | 001 | 2018-04-09 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | Orphan | search |
| Glaxosmithkline Llc | BENLYSTA | belimumab | INJECTABLE;INJECTION | 761043 | 001 | 2017-07-20 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | search | |
| Wyeth Pharms Inc | BESPONSA | inotuzumab ozogamicin | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 761040 | 001 | 2017-08-17 | Start Trial | biOasis Technologies, Inc. (Richmond, CA) | 2033-03-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,364,567
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014160438 | Start Trial |
| United States of America | 10772939 | Start Trial |
| United States of America | 2014322132 | Start Trial |
| United States of America | 2016324937 | Start Trial |
| United States of America | 2019008929 | Start Trial |
| United States of America | 9993530 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
